Matthew Goetz, M.D., professor of oncology at the Mayo Clinic where he is also co-leader of the Women's Cancer Program and chair of the Breast Cancer Disease-Oriented Group, discusses the research he presented at the 2018 San Antonio Breast Cancer Symposium on patient-reported outcomes from women being treated with Verzenio (chemical name: abemaciclib) plus an aromatase inhibitor as the first treatment for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.
Listen to the podcast to hear Dr. Goetz talk about:

what patient-reported outcomes are and why they're important for both doctors and patients

the Verzenio side effects reported in the study

how diarrhea caused by Verzenio can be proactively managed so a woman doesn't have to plan her life around a side effect